Stock Quote
Isis Pharmaceuticals, Inc. (ISIS.W) (NASD ADF)
$11.50
18 Nov 2009
-2.62%
$11.81
$11.50
2,000
$11.50
$11.50
$18.81
$9.90
1.08
2,350,742
ISIS.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Crooke, Stanley | Chairman of the Board, President, Chief Executive Officer | 2,290,191 |
| Parshall, B. Lynne | Chief Financial Officer, Chief Operating Officer, Secretary, Director | 1,476,058 |
| Bennett, C. Frank | Senior Vice President - Antisense Research | 799,256 |
Profile
Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in a two principal segments: Drug Discovery and Development and Regulus Therapeutics Inc. Within the Drug Discovery and Development segment,... Full Description
Company Address
Isis Pharmaceuticals, Inc.
1896 Rutherford Road
Carlsbad CA 92008
P: +1760.9319200
F: +1760.9319639
1896 Rutherford Road
Carlsbad CA 92008
P: +1760.9319200
F: +1760.9319639
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Johnson & Johnson | $62.69 | +0.38 |
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| Merck & Co., Inc. | $36.42 | -0.04 |
| ISIS.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 12.80 |
| P/S(TTM) | 9.29 | 29.90 |
| ROI(TTM) | -4.17 | 2.35 |
| ROE(TTM) | -8.79 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.12 |
| EPS Est. (Current Year) | 1.50 |
| Total Revenue | $26.77M |
| Net Income | $-8.06M |
| EPS | $-0.07 |
